The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry 1, defining the potential prognostic ...
New research from NYU Langone Health detects microplastics in 9 out of 10 prostate cancer tumours, with levels 2.5× higher ...
In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...
Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
A study led by experts at the University of Oxford found a lower risk of prostate and kidney cancer, among others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results